Endocrinology and Dialysis: Management of Lipid Abnormalities Associated with End-Stage Renal Disease-Reference-Cited by-同舟云学术

Endocrinology and Dialysis: Management of Lipid Abnormalities Associated with End-Stage Renal Disease

Published:2006-09-12 Issue:5 Volume:19 Page:391-401
ISSN:0894-0959
Container-title:Seminars in Dialysis
language:en
Short-container-title:

Author:

Liu Jia,Kalantarinia Kambiz,Rosner Mitchell H.

Publisher

Wiley

Subject

Nephrology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1525-139X.2006.00193.x/fullpdf

Reference136 articles.

1. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial;Heart Protection Study Collaborative Group;Lancet,2002

2. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial;Colhoun;Lancet,2004

3. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West Scotland Coronary Prevention Study Group;Shepherd;N Engl J Med,1995

4. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S);Lancet,1994

5. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial Investigators;Sacks;N Engl J Med,1996

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dyslipidemia in renal disease: Causes, consequences and treatment;Endocrinología y Nutrición;2010-11

2. Cholesterol Management in Patients with Chronic Kidney Disease;Therapy in Nephrology & Hypertension;2008